


WHAT IS CLAIMED IS:

1. A compound of Formula I:



wherein

R^1 is selected from 1) substituted or unsubstituted C_1 - C_{10} alkyl, 2) substituted or unsubstituted aryl, 3) substituted or unsubstituted heterocyclyl, and 4) substituted or unsubstituted C_3 - C_{10} cycloalkyl;

R^2 is selected from 1) halogen, 2) substituted or unsubstituted C_1 - C_{10} alkyl, 3) substituted or unsubstituted C_2 - C_{10} alkynyl, 4) substituted or unsubstituted phenyl, and 5) substituted or unsubstituted heterocyclyl selected from pyridyl, benzofuranyl, isoxazolyl, furyl, pyrrolyl, and thienyl; said alkyl, alkynyl, phenyl, and heterocyclyl is optionally substituted with one or more of R^3 ;

R^3 is independently selected from 1) halogen, 2) $-OR^4$, 3) substituted or unsubstituted C_1 - C_{10} alkyl, 4) substituted or unsubstituted C_3 - C_{10} cycloalkyl, 5) substituted or unsubstituted aryl, 6) substituted or unsubstituted aralkyl, 7) substituted or unsubstituted heterocyclyl, 8) $-C(O)R^4$, 9) $-C(O)OR^4$, 10) $-CN$, and 11) $-NO_2$;

R^4 is independently selected from 1) hydrogen, 2) substituted or unsubstituted C_1 - C_{10} alkyl, 3) substituted or unsubstituted C_2 - C_{10} alkenyl, 4) substituted or unsubstituted C_2 - C_{10} alkynyl, 5) substituted or unsubstituted aryl, and 6) substituted or unsubstituted heterocyclyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to Claim 1,

wherein

R^1 is substituted or unsubstituted C_1 - C_6 alkyl;

R² is selected from 1) halogen, 2) substituted or unsubstituted C₂-C₁₀ alkynyl, 3) substituted or unsubstituted phenyl, and 4) substituted or unsubstituted heterocyclyl selected from pyridyl, benzofuranyl, isoxazolyl, furyl, pyrrolyl, and thienyl;

5 said alkynyl, phenyl, and heterocyclyl is optionally substituted with one or more of R³;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound according to Claim 2,

10 wherein

R² is halogen;

or a pharmaceutically acceptable salt or stereoisomer thereof.

15

4. A compound selected from

tert-butyl 3-ethyl-5-formyl-4-iodo-1H-pyrrole-2-carboxylate;

tert-butyl 3-ethyl-5-formyl-4-(pyridin-2-ylethynyl)-1H-pyrrole-2-carboxylate;

20 tert-butyl 3-ethyl-5-formyl-4-(6-methoxypyridin-2-yl)-1H-pyrrole-2-carboxylate;

tert-butyl 4-(1-benzofuran-2-yl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;

tert-butyl 4-(3,5-dimethylisoxazol-4-yl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;

tert-butyl 4-(4-fluorophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;

tert-butyl 4-(4-chlorophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;

25 tert-butyl 3-ethyl-5-formyl-4-(5-formyl-2-furyl)-1H-pyrrole-2-carboxylate;

tert-butyl 3-ethyl-5-formyl-4-phenyl-1H-pyrrole-2-carboxylate;

di(tert-butyl) 4'-ethyl-2'-formyl-1H,1'H-2,3'-bipyrrole-1,5'-dicarboxylate;

tert-butyl 3-ethyl-5-formyl-4-(2-formylthien-3-yl)-1H-pyrrole-2-carboxylate;

tert-butyl 4-(4-cyanophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;

30 ethyl 3-ethyl-5-formyl-4-methyl-1H-pyrrole-2-carboxylate;

ethyl 3,4-diethyl-5-formyl-1H-pyrrole-2-carboxylate;

tert-butyl 3-ethyl-5-formyl-4-(4-nitrophenyl)-1H-pyrrole-2-carboxylate;

tert-butyl 3-ethyl-5-formyl-4-[4-(methoxycarbonyl)phenyl]-1H-pyrrole-2-carboxylate;

tert-butyl 4-(2-cyanophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;

35 tert-butyl 4-(3-cyanophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;


tert-butyl 4-(3-chlorophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;
tert-butyl 4-(2,6-difluorophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-(5-methyl-2-furyl)-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-(4-methylphenyl)-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-(3-methylphenyl)-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-(2-methylphenyl)-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-thien-3-yl-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-thien-2-yl-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-(3-methoxyphenyl)-1H-pyrrole-2-carboxylate;
tert-butyl 3-ethyl-5-formyl-4-(2-methoxyphenyl)-1H-pyrrole-2-carboxylate;

or a pharmaceutically acceptable salts or stereoisomer thereof.

15

5. The compound according to Claim 4 that is

tert-butyl 3-ethyl-5-formyl-4-iodo-1H-pyrrole-2-carboxylate




20 or a pharmaceutically acceptable salt or stereoisomer thereof.

6. The compound according to Claim 4 that is

tert-butyl 3-ethyl-5-formyl-4-phenyl-1H-pyrrole-2-carboxylate


25



or a pharmaceutically acceptable salt or stereoisomer thereof.

7. The compound according to Claim 4 that is


tert-butyl 3-ethyl-5-formyl-4-(2-formylthien-3-yl)-1H-pyrrole-2-carboxylate



or a pharmaceutically acceptable salt or stereoisomer thereof.

8. The compound according to Claim 4 that is


tert-butyl 4-(2-cyanophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate



or a pharmaceutically acceptable salt or stereoisomer thereof.

9. The compound according to Claim 4 that is

tert-butyl 4-(2,6-difluorophenyl)-3-ethyl-5-formyl-1H-pyrrole-2-carboxylate



or a pharmaceutically acceptable salt or stereoisomer thereof.

10. A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

5 11. A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

12. The method of Claim 11 wherein the protein kinase is an RTK.

10 13. The method of Claim 12, wherein the RTK is selected from IR, IGF-1R and IRR.

14. A method of treating a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

15 15. A method of Claim 14, wherein the PK-related disorder is an IGF-1R-related disorder selected from: 1) cancer, 2) diabetes, 3) an autoimmune disorder, 4) a hyperproliferation disorder, 5) aging, 6) acromegaly, and 7) Crohn's disease.

20 16. A method of preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

17. A method of Claim 16, wherein the PK-related disorder is an IGF-1R-related disorder selected from: 1) cancer, 2) diabetes, 3) an autoimmune disorder, 4) a hyperproliferation disorder, 5) aging, 6) acromegaly, and 7) Crohn's disease.

25 18. A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

19. A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.